When federal health officials publicly endorsed leucovorin as an autism treatment in September 2025, they set in motion a cascade that reveals how swiftly institutional authority can reshape medical practice — even in the absence of evidence. Within days, pediatric prescriptions surged across the country, not because the science had changed, but because the government had spoken. The episode raises an enduring question about the weight of public trust: when those entrusted with protecting health speak prematurely, who bears the cost of that miscalculation?
Federal autism claims sparked 46% spike in unproven leucovorin use for children
Children with autism may be exposed to unproven treatments with unknown long-term safety profiles, while cancer patients face reduced access to leucovorin due to supply shortages.
The government's messaging about medications must rest on rigorous evidence
Mark
Why did federal officials promote leucovorin for autism if the evidence wasn't there?
Mimi
The press conference was ostensibly about updating the drug's label for cerebral folate deficiency, which is legitimate. But they went beyond that narrow claim and endorsed it for autism more broadly, even though only small studies existed.
Mark
Did they know the evidence was weak?
Mimi
That's the question. They may have believed the preliminary findings were promising enough to mention. But there's a difference between "this warrants further study" and "this is an effective treatment."
Mark
What happens to the children who got prescribed leucovorin after that press conference?
Mimi
That's the hardest part. Most of them are now taking a drug with unknown long-term effects. Some may benefit if they happen to have cerebral folate deficiency. But many are taking it for autism without any proof it will help.
Mark
And the cancer patients?
Mimi
They're caught in the middle. Demand for leucovorin spiked so dramatically that supply couldn't keep up. People who actually need it for chemotherapy are now facing shortages.
Mark
Could this have been prevented?
Mimi
If the federal officials had stuck to what they actually knew—that leucovorin helps with cerebral folate deficiency—and resisted the temptation to claim more, yes. The study shows how powerful government messaging is. That power demands restraint.
Mark
What should happen now?
Mimi
The researchers are essentially calling for the government to be more careful about what it claims in public. And probably, many of those children should be reassessed to see if leucovorin is actually helping them.
Il Polso
- A single federal press conference in September 2025 was enough to drive a 46% spike in leucovorin prescriptions for children within one week — a stark demonstration of how official endorsement can outrun evidence.
- By year's end, weekly pediatric prescriptions had exploded from 734 to 5,858 children, a 700% surge built not on clinical trials but on government messaging that implied settled science where little existed.
- Cancer patients who depend on leucovorin to survive chemotherapy now face worsening drug shortages, as off-label demand for an unproven autism treatment competes with life-sustaining medical need.
- Children with autism are being exposed to a medication with unknown long-term safety profiles, while evidence-based therapies risk being sidelined by the false hope that federal promotion created.
- Researchers are now calling for a reckoning with the obligations of public health authority — arguing that when government speaks about drugs, the standard must be rigorous evidence, not preliminary findings or patient anecdotes.
When federal health officials publicly endorsed leucovorin as an autism treatment in September 2025, they set in motion a cascade that reveals how swiftly institutional authority can reshape medical practice — even in the absence of evidence. Within days, pediatric prescriptions surged across the country, not because the science had changed, but because the government had spoken. The episode raises an enduring question about the weight of public trust: when those entrusted with protecting health speak prematurely, who bears the cost of that miscalculation?
In September 2025, U.S. Department of Health and Human Services officials held a press conference to announce a label update for leucovorin, a decades-old vitamin B9 derivative used primarily to counter chemotherapy side effects. The legitimate purpose was to formally recognize the drug's role in treating cerebral folate deficiency, a rare genetic condition. But officials went further, publicly promoting leucovorin as an effective autism treatment — a claim unsupported by large clinical trials.
The response was immediate and measurable. Within a single week, pediatric prescriptions jumped 46 percent. By the end of 2025, the weekly number of children receiving leucovorin had risen from 734 to 5,858 — a 700 percent increase over the year. A study led by researchers at Michigan Medicine, published in The New England Journal of Medicine, captured 150,026 prescriptions dispensed to nearly 47,400 children from U.S. retail pharmacy data. The surge was most pronounced among children aged six to eleven and in the southern United States; adult prescribing patterns showed no comparable shift, suggesting the federal messaging specifically reshaped pediatric practice.
The scientific foundation for this wave of prescribing was thin. Only small, preliminary studies had hinted at possible benefits for some autistic children. No large randomized trials had established efficacy or safety. Yet the government's public endorsement created the impression of certainty, and some prescribing had already begun climbing before the press conference, driven by earlier media coverage of patient stories.
The ripple effects reached beyond the children receiving the drug. Researchers flagged the likelihood that surging off-label demand was contributing to leucovorin shortages, reducing access for cancer patients who rely on it as part of chemotherapy regimens. For families of autistic children, the concern is more intimate: an unproven treatment promoted with official authority risks displacing therapies with actual evidence behind them, while exposing young patients to a medication whose long-term effects remain unknown.
Lead researcher Kao Ping Chua framed the episode as a lesson in the gravity of institutional speech. Government health officials wield the power to reshape prescribing patterns across an entire nation within days — and that power, he argued, demands a corresponding obligation to ground public messaging in rigorous science rather than hope or preliminary data.
In September 2025, officials from the U.S. Department of Health and Human Services held a press conference to announce plans for updating leucovorin's medical label. The drug, a form of vitamin B9 that has been in use for decades, was being formally recognized for treating cerebral folate deficiency, a rare genetic condition. But during that same event, federal officials went further, promoting leucovorin as an effective autism treatment—a claim that lacked substantial scientific backing.
The consequences were swift and measurable. Within a single week of the press conference, prescriptions for leucovorin among children aged zero to seventeen jumped 46 percent, climbing from 4.6 children per 100,000 to 6.7 per 100,000. By the end of 2025, the picture was even starker: the weekly number of children receiving leucovorin prescriptions had surged from 734 to 5,858—a 700 percent increase across the full year. These figures come from a new study led by researchers at Michigan Medicine and published in The New England Journal of Medicine, which analyzed data representing nearly all prescriptions filled in U.S. retail pharmacies. The database captured 150,026 leucovorin prescriptions dispensed to 47,394 children during 2025 alone.
The spike was not uniform across the country or across age groups. The largest increases occurred among children ages six to eleven and in the southern United States. Notably, leucovorin prescriptions to adults did not experience a similar surge after the press conference, suggesting that the federal messaging specifically influenced pediatric prescribing patterns. Kao Ping Chua, a pediatrician and lead author of the study at the University of Michigan's C.S. Mott Children's Hospital, described the findings as concerning. The effectiveness and long-term safety of leucovorin for children with autism remain uncertain, he noted, yet the federal government's public endorsement had driven widespread off-label use of the drug.
Historically, leucovorin has served a narrow but important purpose: countering the toxic side effects of methotrexate, a chemotherapy and immunosuppressant medication. A handful of small studies have suggested the drug might help improve some autism symptoms in certain children, but no large randomized clinical trials have been conducted to establish efficacy or safety. The federal messaging, however, created the impression of settled science. Some of the prescribing surge may have begun even before the September press conference, driven by earlier news coverage featuring patient stories that resonated with families seeking treatments for autism.
The consequences extend beyond the children receiving leucovorin. Researchers have raised the possibility that increased off-label demand for the drug has contributed to ongoing shortages in the pharmaceutical supply chain, reducing access for cancer patients who depend on leucovorin as part of their treatment regimen. For families of children with autism, the concern is more direct: the promotion of an unproven treatment risks creating false hope, potentially displacing evidence-based therapies while exposing young children to a medication whose long-term effects remain unknown.
Chua emphasized what the study reveals about the reach of federal authority. When government health officials speak publicly about medications, their words carry weight that can reshape prescribing patterns across the country within days. That power, he argued, carries an obligation: the government's messaging about drugs must rest on rigorous evidence, not speculation or preliminary findings. The 2025 leucovorin episode stands as a cautionary example of what happens when that standard is not met.
Citazioni salienti
Our findings suggest the press conference may have increased off-label prescribing of leucovorin to children with autism. This increase is concerning because the effectiveness and long-term safety of leucovorin for children with autism is uncertain.— Kao Ping Chua, M.D., Ph.D., lead author and pediatrician at University of Michigan Health
Our findings demonstrate the power of the federal government to influence medical practice. Given this power, it is important that the government's messaging about medications is based on rigorous evidence.— Kao Ping Chua
Vuoi la storia completa?
Leggi l'originale su News-Medical ↗
Health & Medicine